HOPA Ahead

Articles

What considerations should pharmacists keep in mind when treating patients with chronic lymphocytic leukemia?

Patient-Specific Factors to Consider in CLL Treatment Management

Bernard Marini, PharmD, BCOP, gives an overview of selecting the most effective, safest, and most cost-effective acute myeloid leukemia treatments for patients. 

Factors Affecting Patient Selection for AML Therapies

The high cost of targeted treatments for acute myeloid leukemia has made it difficult for patients to access these therapies. 

Challenges in the Use of Targeted Therapies for AML

Lisa Holle, PharmD, BCOP, FHOPA, associate clinical professor at the University of Connecticut discusses key trials in prostate cancer research.

Key Trials for Pharmacists to Know in Prostate Cancer Research

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed the recent updates to the American Cancer Society's screening guidelines for colorectal cancer. 

ACS Screening Guideline Updates for Colorectal Cancer

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, provides an overview of the evolving treatment paradigm for chronic lymphocytic leukemia. 

CLL Treatment Paradigm Evolving with Availability of Oral Chemotherapy

Alison Duffy, PharmD, BCOP, from UM Greenebaum Comprehensive Cancer Center, discusses the importance of the pharmacist's role in the management of chronic lymphocytic leukemia treatments. 

The Pharmacist's Role in Management of CLL Treatment

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, explains how pharmacists can counsel patients about risk factors for colorectal cancer and reduction strategies. 

Counseling Patients on Risk Factors, Reduction Strategies for Colorectal Cancer

Amber Draper, PharmD, BCOP, clinical pharmacist at Winship Cancer Institute, discussed emerging trends in oncology care. 

Personalized Medicine: An Emerging Trend in Cancer Care

In this clip, Bernard Marini, PharmD, BCOP, inpatient hematology specialist at the University of Michigan, discusses how IDH inhibitors like ivosidenib and enasidenib fit into the treatment landscape for patients with relapsed or refractory acute myeloid leukemia. 